002872 ST天圣制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.247-2.801-4.267-4.355-4.065
总资产报酬率 ROA (%)-0.928-2.060-3.151-3.220-2.974
投入资产回报率 ROIC (%)-1.039-2.317-3.574-3.701-3.376

边际利润分析
销售毛利率 (%)48.84349.11647.65247.08356.574
营业利润率 (%)-10.038-12.271-16.505-16.152-13.955
息税前利润/营业总收入 (%)-8.481-11.228-16.092-15.196-12.495
净利润/营业总收入 (%)-10.573-10.895-15.472-16.176-15.083

收益指标分析
经营活动净收益/利润总额(%)183.115105.86273.922101.621125.389
价值变动净收益/利润总额(%)-15.445-10.106-16.938-2.123-5.850
营业外收支净额/利润总额(%)0.517-2.0273.8431.214-0.701

偿债能力分析
流动比率 (X)1.3501.6351.9551.5201.469
速动比率 (X)1.1501.3911.6581.2211.234
资产负债率 (%)24.69525.92126.38025.44526.360
带息债务/全部投入资本 (%)10.26911.57610.4736.8267.155
股东权益/带息债务 (%)817.152715.236788.7911,244.1261,188.356
股东权益/负债合计 (%)303.817284.670277.872292.414278.749
利息保障倍数 (X)-5.271-14.064-15.000-13.169-9.164

营运能力分析
应收账款周转天数 (天)80.97481.60384.23590.60092.643
存货周转天数 (天)148.480143.204146.673156.822174.443